Retatrutide 3-GLP | Triple-Receptor Precision
Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, offering researchers a uniquely powerful tool for studying multi-pathway metabolic modulation. Where single-receptor peptides hit one lever, Retatrutide engages the full axis.
Formulated to the Transduction Standard:
-
Triple-Receptor Activity: Simultaneous GLP-1, GIP, and glucagon receptor agonism in a single compound – ideal for comparative and mechanistic metabolic research.
-
99%+ Verified Purity: Every current reference lot undergoes independent third-party HPLC analysis with results published in our open COA Library.
-
Protocol-Ready: Pair with our standardized handling frameworks for reconstitution guidance and storage parameters.
COMPLIANCE NOTICE: This compound is provided strictly for in vitro laboratory research use only. It is not an FDA-approved drug and is not intended for human consumption, clinical administration, or therapeutic use of any kind.
